Evidence map›Paper›PMID 35134818›Full record

Trial reportThe American journal of clinical nutrition2022

Assessing the validity of plasma phospholipid fatty acids as biomarkers of dairy fat intake using data from a randomized controlled intervention trial.

Hilary J Bethancourt, Kelsey A Schmidt, Gail Cromer, Maggie S Burhans, Jessica N Kuzma, Derek K Hagman, Imashi Fernando, Merideth Murray, Kristina M Utzschneider, Sarah Holte and 3 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of clinical nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Hilary J BethancourtDepartment of Anthropology, Northwestern University, Evanston, IL, USA.ORCID 0000-0001-5774-7525
Kelsey A SchmidtDivision of Public Health Sciences, Fred Hutchinson Cancer Prevention Program, Seattle, WA, USA.ORCID 0000-0002-9916-1634
Gail CromerDivision of Public Health Sciences, Fred Hutchinson Cancer Prevention Program, Seattle, WA, USA.
Maggie S BurhansDivision of Public Health Sciences, Fred Hutchinson Cancer Prevention Program, Seattle, WA, USA.ORCID 0000-0002-8277-3765
Jessica N KuzmaDivision of Public Health Sciences, Fred Hutchinson Cancer Prevention Program, Seattle, WA, USA.ORCID 0000-0003-0897-3512
Derek K HagmanDivision of Public Health Sciences, Fred Hutchinson Cancer Prevention Program, Seattle, WA, USA.ORCID 0000-0003-2877-2304
Imashi FernandoDivision of Public Health Sciences, Fred Hutchinson Cancer Prevention Program, Seattle, WA, USA.
Merideth MurrayDivision of Public Health Sciences, Fred Hutchinson Cancer Prevention Program, Seattle, WA, USA.
Kristina M UtzschneiderVA Puget Sound Health Care System, Seattle, WA, USA.ORCID 0000-0002-4924-196X
Sarah HolteDivision of Public Health Sciences, Fred Hutchinson Cancer Prevention Program, Seattle, WA, USA.ORCID 0000-0001-7569-3700
Ross L PrenticeDivision of Public Health Sciences, Fred Hutchinson Cancer Prevention Program, Seattle, WA, USA.ORCID 0000-0003-2849-5757
Jana KraftDepartment of Animal and Veterinary Sciences, University of Vermont, Burlington, VT, USA.ORCID 0000-0003-3445-2710
Mario KratzDivision of Public Health Sciences, Fred Hutchinson Cancer Prevention Program, Seattle, WA, USA.ORCID 0000-0003-2660-8033
University of Washington · USFred Hutch Cancer Center · USNorthwestern University · USUniversity of Vermont · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
PILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON · 1986 to 2026
$30.4M
WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1M
Diabetes, Obesity and Metabolism Training ProgramT32DK007247 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON, KRISTINA Marie UTZSCHNEIDER · 1986 to 2026
$10.0M
Cancer Prevention Trng-Nutrition, Exercise &GeneticsR25CA094880 · NCI · UNIVERSITY OF WASHINGTON · PI WHITE, EMILY · 2002 to 2016
$7.3M
Nutrition, Obesity and Atherosclerosis Training ProgramT32HL007028 · NHLBI · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1985 to 2026
$6.4M
Contributing Factors and Consequences of Cancer Health DisparitiesT32CA094880 · NCI · UNIVERSITY OF WASHINGTON · PI Christopher I Li, AMANDA IRENE PHIPPS · 2017 to 2026
$3.7M
NCI NIH HHS P30 CA015704NCI NIH HHS R25 CA094880NCI NIH HHS T32 CA094880NHLBI NIH HHS T32 HL007028NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK035816NIDDK NIH HHS T32 DK007247NIH HHS P30 DK017047
6 · The paper itself

Abstract

backgroundPlasma phospholipid pentadecanoic acid (C15:0), heptadecanoic acid (C17:0), and trans-palmitoleic acid (trans-C16:1n-7) are correlates of dairy fat intake. However, their relative concentrations may be influenced by other endogenous factors, such as liver fat content, and their validity as biomarkers of dairy fat intake has yet to be established.

objectivesWe investigated whether liver fat content modifies relations between concentrations of C15:0, C17:0, and trans-C16:1n-7 (alone and in combination with iso-C17:0) and known dairy fat intake in the context of a randomized controlled intervention study. We further examined the proportion of dairy fat intake explained by these fatty acids on their own and when considering liver fat content.

methodsWe used data from a 12-wk intervention trial in which participants (n = 62) consumed diets limited in dairy (0.3 g/d of dairy fat), rich in low-fat dairy (8.7 g/d of dairy fat), or rich in full-fat dairy (28.5 g/d of dairy fat). We used linear regression models to examine relations between relative fatty acid concentrations and grams per day of dairy fat intake, liver fat percentage, and their interaction.

resultsOnly trans-C16:1n-7 in isolation (β: 0.0004 ± 0.0002, P = 0.03) and combined with iso-C17:0 (β: 0.002 ± 0.0005, P < 0.0001) were consistently positively associated with dairy fat intake regardless of liver fat content. Trans-C16:1n-7 combined with iso-C17:0 also explained the greatest proportion of variation (35.4%) in dairy fat intake. C15:0 and C17:0 were not associated with dairy fat intake after adjusting for liver fat and were predicted to be higher in relation to increased dairy fat intake only among individuals with elevated liver fat.

conclusionsThe potential for liver fat to affect relative plasma phospholipid concentrations of C15:0 and C17:0 raises questions about their validity as biomarkers of dairy fat intake. Of the fatty acid measures tested, trans-C16:1n-7 combined with iso-C17:0, especially with adjustment of liver fat, age, and sex, may provide the most robust estimate of dairy fat consumption.

Indexed as

Dietary FatsPhospholipidsBiomarkersDairy ProductsDiet, Fat-RestrictedFatty AcidsHumansBiomarkersDietary FatsFatty AcidsPhospholipidsbiomarkerdairyfull-fat dairyliver fatplasma phospholipid fatty acids

Identifiers

PMID35134818
PMCPMC9170464
OpenAlexW4210258328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.